November 3, 2021 -- Model Medicines has raised $4.1 million to bolster its therapeutic pipeline for challenging and rare diseases in oncology, infectious diseases, and gastric disorders.
Funds will be used to advance the company's drug development programs, including advancing in vitro validated candidates to preclinical proof of concept and its lead asset, MDL-001, an oral infectious disease drug candidate, toward an investigational new drug submission.
The oversubscribed financing round received participation from 8VC, Irving Investors, Particle X, and Nex Cubed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
